Second Department of Paediatrics, Children's Hospital 'P. & A. Kyriakou, National and Kapodistrian University of Athens, Athens, Greece.
Department of Endocrinology, Growth and Development, 'P. & A. Kyriakou Children's Hospital, Athens, Greece.
Endocr Regul. 2020 Jul 1;54(3):227-229. doi: 10.2478/enr-2020-0025.
Aldosterone synthase deficiency (ASD) is a rare, autosomal recessive inherited disease with an overall clinical phenotype of failure to thrive, vomiting, severe dehydration, hyperkalemia, and hyponatremia. Mutations in the CYP11B2 gene encoding aldosterone synthase are responsible for the occurrence of ASD. Defects in CYP11B2 gene have only been reported in a limited number of cases worldwide. Due to this potential life-threatening risk, comprehensive hormonal investigation followed by genetic confirmation is essential for the clinical management of offsprings.
We herein describe an unusual case of ASD type II in a neonate with faltering growth as a single presenting symptom. To our knowledge, this is the first Greek case of ASD type II reported with confirmed genetic analysis. Next generation sequencing of her DNA revealed the homozygous mutation p.T185I (ACC-ATC) (c.554C>T) (g.7757C>T) in exon 3 of the CYP11B2 gene in the neonate, inherited from both parents who were heterozygotes for the mutation.
Physicians handling neonates with faltering growth, particularly in the initial six weeks of life, should be suspicious of mineralocorticoid insufficiency either as isolated hypoaldosteronism or in the context of congenital adrenal hyperplasia. Essential investigations should be performed and appropriate treatment should be administered promptly without awaiting for the hormonal profile results. Interpretation of the clinical picture and the hormonal profile will guide the analysis of candidate genes. Primary selective hypoaldosteronism is a rare, life threatening disease, but still with an unknown overall population impact. Thus, reporting cases with confirmed gene mutations is of major importance.
醛固酮合酶缺乏症(ASD)是一种罕见的常染色体隐性遗传性疾病,其总体临床表型为生长不良、呕吐、严重脱水、高钾血症和低钠血症。编码醛固酮合酶的 CYP11B2 基因突变是 ASD 发生的原因。CYP11B2 基因突变仅在全球有限数量的病例中报道过。由于这种潜在的危及生命的风险,全面的激素调查后进行基因确认对于后代的临床管理至关重要。
我们在此描述了一例以生长不良为唯一表现的新生儿 II 型 ASD 不寻常病例。据我们所知,这是首例报道的希腊 II 型 ASD 病例,经基因分析证实。对其 DNA 的下一代测序显示,新生儿 CYP11B2 基因第 3 外显子中的纯合突变 p.T185I(ACC-ATC)(c.554C>T)(g.7757C>T),由父母双方均为该突变的杂合子遗传而来。
处理生长不良的新生儿的医生,特别是在生命的最初 6 周内,应怀疑是否存在盐皮质激素不足,无论是孤立性低醛固酮症还是先天性肾上腺增生症。应进行必要的检查,并在等待激素谱结果之前迅速给予适当的治疗。对临床表现和激素谱的解读将指导候选基因的分析。原发性选择性低醛固酮症是一种罕见的、危及生命的疾病,但总体人群的影响仍未知。因此,报告有明确基因突变的病例非常重要。